Last reviewed · How we verify
Gemcitabine plus Abraxane
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while Abraxane (paclitaxel albumin-bound) stabilizes microtubules to prevent cell division, together providing synergistic cytotoxic effects against cancer cells.
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while Abraxane (paclitaxel albumin-bound) stabilizes microtubules to prevent cell division, together providing synergistic cytotoxic effects against cancer cells. Used for Pancreatic cancer (phase 3 development).
At a glance
| Generic name | Gemcitabine plus Abraxane |
|---|---|
| Also known as | Gemzar, nab-paclitaxel, onxol |
| Sponsor | ERYtech Pharma |
| Drug class | Chemotherapy combination (nucleoside analog + taxane) |
| Target | DNA synthesis (gemcitabine); tubulin/microtubules (paclitaxel) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine acts as a deoxycytidine analog that is incorporated into DNA and inhibits ribonucleotide reductase, disrupting DNA synthesis and triggering apoptosis. Abraxane is a nanoparticle albumin-bound formulation of paclitaxel that binds to tubulin and stabilizes microtubules, preventing mitotic spindle formation. The combination leverages complementary mechanisms of action to enhance cytotoxicity in rapidly dividing cancer cells.
Approved indications
- Pancreatic cancer (phase 3 development)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Neuropathy
- Nausea and vomiting
- Fatigue
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (PHASE2)
- CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine plus Abraxane CI brief — competitive landscape report
- Gemcitabine plus Abraxane updates RSS · CI watch RSS
- ERYtech Pharma portfolio CI